Kaleebu, Pontiano; Levin, Jonathan; Nanvubya, Annet; Kibengo, Freddie; Jaoko, Walter; Pala, Pietro; Perreau, Matthieu; Namuniina, Annemarie; Kitandwe, Paul; Tapia, Gonzalo; +20 more... Serwanga, Jennifer; Yates, Nicole; Fast, Pat; Mayer, Bryan; Montefiori, David; Tomaras, Georgia; Robb, Merlin; Lee, Carter; Wagner, Ralf; Sanders, Edward; Kilembe, William; Kiwanuka, Noah; Gilmour, Jill; Kuipers, Hester; Vooij, Dani; Chinyenze, Kundai; Priddy, Frances; Ding, Song; Hanke, Tom; Pantaleo, Giuseppe; (2017) THE RESULTS OF THE EV06 DNA-PROTEIN COMBINATION TRIAL AND PLANS FOR GREAT, AN EDCTP2-FUNDED CONSERVED-MOSAIC EPITOPE HIV VACCINE TRIAL. BMJ Global Health, 2 (Suppl). A16.2-A16. DOI: https://doi.org/10.1136/bmjgh-2016-000260.39

Downloaded from: http://researchonline.lshtm.ac.uk/4651028/

DOI: https://doi.org/10.1136/bmjgh-2016-000260.39

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Methods EV06 enrolled 72 males and females aged 18–45, half infected with *S. mansoni* (SM+). In each arm 30 received vaccine and 6 placebo at week 0, 4 and 24. Responses were evaluated at week 0, 6, 26 and 36. Humoral responses were measured as binding IgG against a panel of HIV-1 envelope glycoproteins and as neutralizing antibodies (Nabs), using TZM/blk cells and tier 1 pseudoviruses. Cellular responses were measured as HIV-specific CD4+ and CD8+ T-cell by IFN-γ ELISPOT and multi-cytokine intracellular staining flow cytometry. GREAT will be a phase IIA trial and preparation for efficacy trials in Kenya, Uganda and Zambia testing ChAdOx1.nVHIVcons5 and ChAdOx1.nVHIVcons6 followed by MVA.tHIVcons3 and MVA.tHIVcons4 on week 2 (Arm 1) or week 8 (Arm 2).

Progress Differences in binding IgG response rates were observed in vaccinated participants against the vaccine matched clade C V1V2 (gp70–96ZM651.02 V1V2) at week 6: 56% among SM+ versus 86% among SM (p=0.039). At week 36, response magnitudes were statistically lower in the SM+ against gp120 and gp140 proteins (p=0.04 for both). SM+ also had lower Nabs and ELISPOT responses at various time points. Still blinded data on the first 20 volunteers show 80% responders for CD4 T cell at w26 and 70% CD8 responders at w36. These trials will provide more data on challenges facing HIV vaccine development in Africa.